Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTB003 in Moderate-to-Severe Thyroid Eye Disease (Ib/II)
CTR20260292Phase 2Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Graves Orbitopathy (GO) comparing NTB003 injection with Placebo injection (2 arms). Primary endpoints: Proptosis response rate at Week 12 and Safety - adverse events. Started Jul 2026; status: active.
02
Drugs
NTB003
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on CTR20260292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260292.